TRACIE J LEONHARDT

Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism LARGO, FL NPI 1588601751

General Payments — all program years on this page

$2,081.26

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 115
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $302.17 across 18 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $302.1718

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $181.4011
Acerta Pharma LLC $46.343
Lilly USA, LLC $32.912
CSL Behring $22.721
Abbott Laboratories $18.801

By program year

Program yearAmountRecords
2018 $178.339
2019 $176.6012
2020 $388.2524
2021 $263.0515
2022 $271.5213
2023 $501.3424
2024 $302.1718

Records — PY2024 (18)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1104542694 AstraZeneca Pharmaceuticals LP $14.77 01/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105545687 AstraZeneca Pharmaceuticals LP $15.42 08/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105704476 AstraZeneca Pharmaceuticals LP $16.15 06/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125139498 Abbott Laboratories $18.80 07/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1134619167 CSL Behring $22.72 05/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135483793 Lilly USA, LLC $16.64 05/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135489724 Lilly USA, LLC $16.27 09/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137618101 Takeda Pharmaceuticals U.S.A., Inc. $29.66 01/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137618105 Takeda Pharmaceuticals U.S.A., Inc. $4.55 01/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137618109 Takeda Pharmaceuticals U.S.A., Inc. $15.68 02/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137618112 Takeda Pharmaceuticals U.S.A., Inc. $4.96 02/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137618116 Takeda Pharmaceuticals U.S.A., Inc. $21.19 04/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137618120 Takeda Pharmaceuticals U.S.A., Inc. $34.05 06/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137618124 Takeda Pharmaceuticals U.S.A., Inc. $2.59 09/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137618127 Takeda Pharmaceuticals U.S.A., Inc. $30.72 09/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137618131 Takeda Pharmaceuticals U.S.A., Inc. $13.42 10/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137618135 Takeda Pharmaceuticals U.S.A., Inc. $1.51 11/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137618138 Takeda Pharmaceuticals U.S.A., Inc. $23.07 11/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.